Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,038,000
  • Shares Outstanding, K 77,500
  • Annual Sales, $ 361,050 K
  • Annual Income, $ -74,400 K
  • EBIT $ -12 M
  • EBITDA $ 16 M
  • 60-Month Beta 1.67
  • Price/Sales 8.40
  • Price/Cash Flow 421.82
  • Price/Book 2.56

Options Overview Details

View History
  • Implied Volatility 68.79% ( -6.36%)
  • Historical Volatility 45.44%
  • IV Percentile 24%
  • IV Rank 56.46%
  • IV High 109.07% on 04/15/24
  • IV Low 16.55% on 05/29/24
  • Put/Call Vol Ratio 0.40
  • Today's Volume 21
  • Volume Avg (30-Day) 88
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 2,357
  • Open Int (30-Day) 2,355

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.14
  • Number of Estimates 2
  • High Estimate 0.15
  • Low Estimate 0.13
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +450.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.93 +22.74%
on 10/23/24
41.43 -5.41%
on 11/07/24
+6.07 (+18.33%)
since 10/21/24
3-Month
28.44 +37.80%
on 09/06/24
41.43 -5.41%
on 11/07/24
+7.56 (+23.90%)
since 08/21/24
52-Week
18.61 +110.59%
on 04/18/24
41.43 -5.41%
on 11/07/24
+14.01 (+55.64%)
since 11/21/23

Most Recent Stories

More News
Veracyte: Q3 Earnings Snapshot

Veracyte: Q3 Earnings Snapshot

VCYT : 39.16 (-0.10%)
HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket

Henry Schein, Inc. HSIC registered adjusted earnings per share (EPS) of $1.22 in the third quarter of 2024, down 7.6% from the year-ago figure. However, the metric exceeded the Zacks Consensus Estimate...

VCYT : 39.16 (-0.10%)
HQY : 103.00 (+0.04%)
HSIC : 72.76 (-1.32%)
PAHC : 23.55 (+0.68%)
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad Laboratories, Inc. BIO posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year...

VCYT : 39.16 (-0.10%)
HQY : 103.00 (+0.04%)
BIO : 322.24 (-0.45%)
PAHC : 23.55 (+0.68%)
WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action

Walgreens Boots Alliance, Inc. WBA delivered adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2024, down 41.8% from the year-ago quarter’s figure (down 40.8% at constant...

VCYT : 39.16 (-0.10%)
HQY : 103.00 (+0.04%)
WBA : 8.18 (-0.73%)
PAHC : 23.55 (+0.68%)
Veracyte: Q2 Earnings Snapshot

Veracyte: Q2 Earnings Snapshot

VCYT : 39.16 (-0.10%)
Veracyte: Q1 Earnings Snapshot

Veracyte: Q1 Earnings Snapshot

VCYT : 39.16 (-0.10%)
Veracyte: Q4 Earnings Snapshot

Veracyte: Q4 Earnings Snapshot

VCYT : 39.16 (-0.10%)
Veracyte: Q3 Earnings Snapshot

Veracyte: Q3 Earnings Snapshot

VCYT : 39.16 (-0.10%)
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?

The genetic test maker is rapidly increasing test volumes.

AZN : 63.74 (+0.85%)
COMP : 6.43 (-0.16%)
VCYT : 39.16 (-0.10%)
Veracyte: Q2 Earnings Snapshot

Veracyte: Q2 Earnings Snapshot

VCYT : 39.16 (-0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 40.99
2nd Resistance Point 40.39
1st Resistance Point 39.80
Last Price 39.16
1st Support Level 38.61
2nd Support Level 38.01
3rd Support Level 37.42

See More

52-Week High 41.43
Last Price 39.16
Fibonacci 61.8% 32.71
Fibonacci 50% 30.02
Fibonacci 38.2% 27.33
52-Week Low 18.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar